Agency Information Collection Activities; Proposed Collection; Comment Request; Evaluation of the Food and Drug Administration's Campaign To Reduce Tobacco Use Among Lesbian, Gay, Bisexual, and Transgender Young Adults, 37270-37273 [2015-16020]
Download as PDF
37270
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0721. Also
include the FDA docket number found
in brackets in the heading of this
document.
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd.; COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Animal Food Labeling; Declaration of
Certifiable Color Additives—21 CFR
501.22(k) OMB Control Number 0910–
0721—Extension
This information collection is
associated with requirements under 21
CFR 501.22(k) in which animal food
manufacturers must declare the
presence of certified and noncertified
color additives in their animal food
products on the product label. The
Agency issued this regulation in
response to the Nutrition Labeling and
Education Act of 1990 (Pub. L. 101–535)
to make animal food regulations
consistent with the regulations
regarding the declaration of color
additives on human food labels and to
provide animal owners with
information on the colors used in
animal food.
Respondents to this collection are
manufacturers of pet food that contain
color additives. Manufacturers of certain
food or food ingredients do not have
products that contain color additives
requiring certification (e.g., food for
chickens, fish, and some other species,
including some pet foods) and would
thus be minimally affected by
§ 501.22(k)(1). However, since we
cannot rule out the possibility that they
may at some point use a color additive
requiring certification, we have
consolidated the burden estimates for
§§ 501.22(k)(1) and 501.22(k)(2).
Additionally, we believe that this
burden is more accurately characterized
as a third-party disclosure burden
because FDA does not require routine
submission of pet food labeling to the
Agency.
In the Federal Register of April 1,
2015 (80 FR 17445), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. One comment was received
but did not respond to any of the four
information collection topics solicited
and is therefore not addressed by the
Agency.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
21 CFR Section/Activity
Number of
respondents
Number of
disclosures
per
respondent
Total annual
disclosures
Average
burden per
disclosure
Total hours
501.22(k); labeling of color additive or make of color additive; labeling of color additives not subject to certification.
3,120
0.83
2,587
.25
(15 minutes)
647
asabaliauskas on DSK5VPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Having become effective November
18, 2013, the Agency estimates that the
burden associated with the labeling
requirements under § 501.22(k) apply
only to new product labels. Because the
vast majority of animal food products
that contain certified color additives are
pet foods, we limit our burden estimate
to reviewing labels for the use of
certified color additives to pet food
manufacturers subject to this regulation.
Based on A.C. Nielsen Data, FDA
estimates that the number of animal
food product units subject to § 501.22(k)
for which sales of the products are
greater than zero is 25,874. Assuming
that the flow of new products is 10
percent per year, then 2,587 new animal
food products subject to § 501.22(k) will
come on the market each year. FDA also
estimates that there are about 3,120
manufacturers of pet food subject to
either § 501.22(k)(1) or (k)(2). Assuming
the approximately 2,587 new products
are split equally among the firms, then
each firm would prepare labels for
approximately 0.83 new products per
year (2,587 new products/3,120 firms is
approximately 0.83 labels per firm).
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
The Agency expects that firms
prepare the required labeling for their
products in a manner that takes into
account at one time all information
required to be disclosed on their
product labels. Based on our experience
with reviewing pet food labeling, FDA
estimates that firms would require less
than 0.25 hour (15 minutes) per product
to comply with the requirement to
include the color additive information
pursuant to § 501.22(k). The total
burden of this activity is 647 hours
(2,587 labels × 0.25 hour/label is
approximately 647 hours).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: June 25, 2015.
Leslie Kux,
Associate Commissioner for Policy.
ACTION:
[FR Doc. 2015–16022 Filed 6–29–15; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Food and Drug Administration
[Docket No. FDA–2015–N–2126]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Evaluation of the
Food and Drug Administration’s
Campaign To Reduce Tobacco Use
Among Lesbian, Gay, Bisexual, and
Transgender Young Adults
AGENCY:
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish a notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
SUMMARY:
E:\FR\FM\30JNN1.SGM
30JNN1
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
the Evaluation of FDA’s Multicultural
Youth Tobacco Prevention Campaigns.
Submit either electronic or
written comments on the collection of
information by August 31, 2015.
DATES:
Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
ADDRESSES:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
Evaluation of FDA’s Campaign To
Reduce Tobacco Use Among Lesbian,
Gay, Bisexual, and Transgender Young
Adults OMB Control Number—0910New
The 2009 Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111–31) amends
the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) to grant FDA
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect public health and to
reduce tobacco use by minors. Section
1003(d)(2)(D) of the FD&C Act (21
U.S.C. 393(d)(2)(D)) supports the
development and implementation of
FDA public education campaigns
related to tobacco use. Accordingly,
FDA is currently developing and
implementing public education
campaigns to help prevent and reduce
tobacco use among lesbian, gay,
bisexual and transgender (LGBT) young
adults and thereby reduce the public
health burden of tobacco. Overall the
campaigns will feature events;
advertisements on television and radio
and in print; digital communications
including social media; and other forms
of media.
In support of the provisions of the
Tobacco Control Act that require FDA to
protect the public health and to reduce
tobacco use, FDA requests OMB
approval to collect information needed
to evaluate FDA’s campaign to reduce
tobacco use among LGBT young adults.
Comprehensive evaluation of FDA’s
public education campaigns is needed
to ensure campaign messages are
effectively received, understood, and
accepted by those for whom they are
intended. Evaluation is an essential
organizational practice in public health
and a systematic way to account for and
improve public health actions.
FDA plans to conduct two studies to
evaluate the effectiveness of its LGBT
young adult tobacco prevention
campaign: (1) An outcome evaluation
study to evaluate the effectiveness of its
LGBT young adult tobacco prevention
campaign, and (2) a media tracking
questionnaire to assess awareness of and
receptivity to campaign messages. The
timing of these studies will be designed
to follow the multiple, discrete waves of
media advertising planned for the
campaigns.
• Outcome Evaluation Study
The outcome evaluation study begins
with a baseline survey of LGBT young
adults aged 18 to 24 before the
campaign launch. The baseline will be
followed by three follow-up surveys of
the target audience of young adults at
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
37271
approximately 6-month intervals after
the campaign’s launch. Information will
be collected about young adult
awareness of and exposure to campaign
events and advertisements and about
tobacco-related knowledge, attitudes,
beliefs, intentions and use, as well as
use of other tobacco products (ecigarettes, hookah, cigars, smokeless
tobacco), marijuana and alcohol.
Information will also be collected on
demographic variables including sexual
orientation, age, sex, race/ethnicity,
education, and primary language.
All information will be collected
through in-person and web-based
questionnaires. Young adult
respondents will be recruited in 30 U.S.
cities (15 campaign and 15 comparison
cities) from two sources: (1) Intercept
surveys in LGBT social venues (e.g.,
bars and nightclubs) identified using a
time location sampling approach, and
(2) through social media advertisements
on Facebook and Twitter targeted at
LGBT 18 to 24-year-olds, living in the
same 30 U.S. cities. Participation in the
study is voluntary.
• Media Tracking Survey
The media tracking survey consists of
assessments of LGBT young adults aged
18 to 24 conducted once yearly post
campaign launch—timing that
complements the outcome evaluation’s
timing. The media tracking survey will
assess awareness of the campaign and
receptivity to campaign messages. These
data will provide critical evaluation
feedback to the campaigns and will be
conducted with sufficient frequency to
match the cyclical patterns of events
and media advertising and variation in
exposure to allow for mid-campaign
refinements. For the media tracking
surveys, we will recruit LGBT young
adults aged 18 to 24 from all campaign
cities through social media.
The information collected is
necessary to inform FDA’s efforts and
measure the effectiveness and public
health impact of the campaigns. Data
from the media tracking surveys will be
used to estimate awareness of and
exposure to the campaigns among young
adults in target markets where the
campaigns are active. Data from the
outcome evaluation study will be used
to examine statistical associations
between awareness of and exposure to
the campaigns and subsequent changes
in specific outcomes of interest, which
will include knowledge, attitudes,
beliefs and intentions related to tobacco
use.
FDA’s burden estimate is based on
prior experience with in-person studies
similar to the Agency’s plan presented
in this document, as well as previous
E:\FR\FM\30JNN1.SGM
30JNN1
37272
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
research using social media advertising
to recruit young adult participants. To
reduce overall burden hours,
participants who screen and complete
the baseline outcome evaluation
questionnaire will be re-contacted to
complete the first follow up campaign
evaluation questionnaire, those who
complete the first follow up campaign
evaluation questionnaire will be recontacted to complete the second follow
up campaign evaluation questionnaire,
and so on. Re-contacted individuals will
not need to complete the screener again.
We expect a 50 percent response rate for
individuals recruited in person and a 30
percent rate for individuals recruited via
social media. In each successive round
of data collection, we expect 50 percent
of re-contacted individuals to complete
the follow up questionnaire, therefore,
additional screenings will be conducted
for each follow up in order to maintain
the target sample size for each follow up
questionnaire.
To obtain the target number of
completed questionnaires (‘‘completes’’)
for the outcome evaluation study,
18,376 young adults (11,810 recruited in
person and 6,566 recruited via social
media) will participate in a screening
process (‘‘screener’’). The estimated
burden per screener is 5 minutes
(0.083), for a total of 1,525 hours (980
hours for participants recruited in
person and 545 hours for persons
recruited via social media). A total of
12,600 LGBT young adults (9,448 of
those screened in person and 3,152 of
those screened through social media)
will complete questionnaires in 4
rounds of data collection (baseline and
three post-campaign rounds). The
estimated burden per complete is 30
minutes (0.5 hour) for the baseline
questionnaire and 40 minutes (0.667
hour) for each follow up complete, for
a total of 7,878 hours (5,906 hours for
those recruited in person and 1,972
hours for those recruited via social
media).
To obtain the target number of
completes for the media tracking survey,
5,000 young adults will be recruited via
social media ads to complete a screener
for all three waves of the media tracking
survey. The estimated burden per
screener response is 5 minutes (0.083
hour), for a total of 414 hours for all
waves of media tracking screener. An
estimated 500 LGBT young adults will
complete each of the three waves of the
media tracking survey (assuming a 30
percent response rate to screeners via
social media). The estimated burden per
completed media tracking questionnaire
is 40 minutes (0.667 hour), for a total of
1,002 hours for the three waves. The
total burden for the media tracking
survey (screeners and completes) is
1,416 hours.
The target number of completed
campaign questionnaires (screeners and
questionnaires for both the outcome
evaluation and media tracking survey)
for all respondents is 37,477. The total
estimated burden is 10,819 hours.
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Type of respondent
Activity
General population—Recruited in person (50%
response rate).
Screener—Baseline—outcome study.
4,724
1
4,724
0.083 (5 min.) ......
392
Screener—First follow
up—outcome study.
Screener—Second follow
up—outcome study.
Screener—Third follow
up—outcome study.
Baseline—outcome evaluation questionnaire.
2,362
1
2,362
0.083 (5 min.) .......
196
2,362
1
2,362
0.083 (5 min.) ......
196
2,362
1
2,362
0.083 (5 min.) ......
196
2,362
1
2,362
0.5 (30 min.) .........
1181
First follow up young
adult outcome evaluation questionnaire.
Second follow up young
adult outcome evaluation questionnaire.
Third follow up young
adult outcome evaluation questionnaire.
Screener—Baseline—outcome study.
2,362
1
2,362
0.667 (40 min.) .....
1575
2,362
1
2,362
0.667 (40 min.) .....
1575
2,362
1
2,362
0.667 (40 min.) .....
1575
2,627
1
2,627
0.083 (5 min.) .......
218
Screener—First follow
up—outcome study.
Screener—Second follow
up—outcome study.
Screener—Third follow
up—outcome study.
Baseline—outcome evaluation questionnaire.
1,313
1
1,313
0.083 (5 min.) .......
109
1,313
1
1,313
0.083 (5 min.) ......
109
1,313
1
1,313
0.083 (5 min.) ......
109
788
1
788
0.5 (30 min.) .........
394
788
1
788
0.667 (40 min.) .....
526
LGBT young adults aged
18–24 in select media
markets—Recruited in
person.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
General population—Recruited via social media
(30% response rate).
LGBT young adults aged
18–24 in select media
markets—Recruited via
social media.
First follow up young
adult outcome evaluation questionnaire.
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
E:\FR\FM\30JNN1.SGM
30JNN1
Total hours
Federal Register / Vol. 80, No. 125 / Tuesday, June 30, 2015 / Notices
37273
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued
Type of respondent
LGBT young adults aged
18–24 in the select
media markets—Recruited via social media.
Number of
respondents
Activity
Second follow up young
adult outcome evaluation questionnaire.
Third follow up young
adult outcome evaluation questionnaire.
1st media tracking
screener.
Total ..........................
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0369]
Product-Specific Bioequivalence
Recommendations; Draft and Revised
Draft Guidances for Industry;
Availability
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of
additional draft and revised draft
product-specific bioequivalence (BE)
recommendations. The
recommendations provide productspecific guidance on the design of BE
studies to support abbreviated new drug
applications (ANDAs). In the Federal
Register of June 11, 2010, FDA
announced the availability of a guidance
for industry entitled ‘‘Bioequivalence
Recommendations for Specific
Products’’ that explained the process
that would be used to make productspecific BE recommendations available
to the public on FDA’s Web site. The BE
SUMMARY:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
1
788
0.667 (40 min.) .....
526
788
1
788
0.667 (40 min.) .....
526
1667
..........................................
[FR Doc. 2015–16020 Filed 6–29–15; 8:45 am]
ACTION:
Total hours
1
1667
0.083 (5 min.) .......
138
500
1
500
0.667 (40 min.) .....
334
1667
1
1667
0.083 (5 min.) .......
138
500
1
500
0.667 (40 min.) .....
334
1667
1
1667
0.083 (5 min.) ......
138
500
1
500
0.667 (40 min.) .....
334
37,477
........................
........................
..............................
10,819
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: June 24, 2015.
Leslie Kux,
Associate Commissioner for Policy.
AGENCY:
Average
burden per
response
Total annual
responses
788
1st media tracking questionnaire.
2nd media tracking
screener.
2nd media tracking questionnaire.
3rd media tracking
screener.
3rd media tracking questionnaire.
1 There
Number of
responses per
respondent
VerDate Sep<11>2014
17:34 Jun 29, 2015
Jkt 235001
recommendations identified in this
notice were developed using the process
described in that guidance.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comments on these draft
and revised draft guidances before it
begins work on the final versions of the
guidances, submit either electronic or
written comments on the draft and
revised draft product-specific BE
recommendations listed in this notice
by August 31, 2015.
ADDRESSES: Submit written requests for
single copies of the individual BE
guidances to the Division of Drug
Information, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10001 New Hampshire
Ave., Hillandale Bldg., 4th Floor, Silver
Spring, MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance recommendations.
Submit electronic comments on the
draft product-specific BE
recommendations to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Xiaoqiu Tang, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Hampshire Ave., Bldg. 75, Rm. 4730,
Silver Spring, MD 20993–0002, 301–
796–5850.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 11,
2010 (75 FR 33311), FDA announced the
availability of a guidance for industry
entitled ‘‘Bioequivalence
Recommendations for Specific
Products’’ that explained the process
that would be used to make productspecific BE recommendations available
to the public on FDA’s Web site at
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm.
As described in that guidance, FDA
adopted this process as a means to
develop and disseminate productspecific BE recommendations and
provide a meaningful opportunity for
the public to consider and comment on
those recommendations. Under that
process, draft recommendations are
posted on FDA’s Web site and
announced periodically in the Federal
Register. The public is encouraged to
submit comments on those
recommendations within 60 days of
their announcement in the Federal
Register. FDA considers any comments
received and either publishes final
recommendations or publishes revised
draft recommendations for comment.
Recommendations were last announced
in the Federal Register on March 9,
2015 (80 FR 12502). This notice
announces draft product-specific
E:\FR\FM\30JNN1.SGM
30JNN1
Agencies
[Federal Register Volume 80, Number 125 (Tuesday, June 30, 2015)]
[Notices]
[Pages 37270-37273]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-16020]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-2126]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Evaluation of the Food and Drug Administration's
Campaign To Reduce Tobacco Use Among Lesbian, Gay, Bisexual, and
Transgender Young Adults
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish a notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on
[[Page 37271]]
the Evaluation of FDA's Multicultural Youth Tobacco Prevention
Campaigns.
DATES: Submit either electronic or written comments on the collection
of information by August 31, 2015.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Evaluation of FDA's Campaign To Reduce Tobacco Use Among Lesbian, Gay,
Bisexual, and Transgender Young Adults OMB Control Number--0910-New
The 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111-31) amends the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) to grant FDA authority to regulate the
manufacture, marketing, and distribution of tobacco products to protect
public health and to reduce tobacco use by minors. Section
1003(d)(2)(D) of the FD&C Act (21 U.S.C. 393(d)(2)(D)) supports the
development and implementation of FDA public education campaigns
related to tobacco use. Accordingly, FDA is currently developing and
implementing public education campaigns to help prevent and reduce
tobacco use among lesbian, gay, bisexual and transgender (LGBT) young
adults and thereby reduce the public health burden of tobacco. Overall
the campaigns will feature events; advertisements on television and
radio and in print; digital communications including social media; and
other forms of media.
In support of the provisions of the Tobacco Control Act that
require FDA to protect the public health and to reduce tobacco use, FDA
requests OMB approval to collect information needed to evaluate FDA's
campaign to reduce tobacco use among LGBT young adults. Comprehensive
evaluation of FDA's public education campaigns is needed to ensure
campaign messages are effectively received, understood, and accepted by
those for whom they are intended. Evaluation is an essential
organizational practice in public health and a systematic way to
account for and improve public health actions.
FDA plans to conduct two studies to evaluate the effectiveness of
its LGBT young adult tobacco prevention campaign: (1) An outcome
evaluation study to evaluate the effectiveness of its LGBT young adult
tobacco prevention campaign, and (2) a media tracking questionnaire to
assess awareness of and receptivity to campaign messages. The timing of
these studies will be designed to follow the multiple, discrete waves
of media advertising planned for the campaigns.
Outcome Evaluation Study
The outcome evaluation study begins with a baseline survey of LGBT
young adults aged 18 to 24 before the campaign launch. The baseline
will be followed by three follow-up surveys of the target audience of
young adults at approximately 6-month intervals after the campaign's
launch. Information will be collected about young adult awareness of
and exposure to campaign events and advertisements and about tobacco-
related knowledge, attitudes, beliefs, intentions and use, as well as
use of other tobacco products (e-cigarettes, hookah, cigars, smokeless
tobacco), marijuana and alcohol. Information will also be collected on
demographic variables including sexual orientation, age, sex, race/
ethnicity, education, and primary language.
All information will be collected through in-person and web-based
questionnaires. Young adult respondents will be recruited in 30 U.S.
cities (15 campaign and 15 comparison cities) from two sources: (1)
Intercept surveys in LGBT social venues (e.g., bars and nightclubs)
identified using a time location sampling approach, and (2) through
social media advertisements on Facebook and Twitter targeted at LGBT 18
to 24-year-olds, living in the same 30 U.S. cities. Participation in
the study is voluntary.
Media Tracking Survey
The media tracking survey consists of assessments of LGBT young
adults aged 18 to 24 conducted once yearly post campaign launch--timing
that complements the outcome evaluation's timing. The media tracking
survey will assess awareness of the campaign and receptivity to
campaign messages. These data will provide critical evaluation feedback
to the campaigns and will be conducted with sufficient frequency to
match the cyclical patterns of events and media advertising and
variation in exposure to allow for mid-campaign refinements. For the
media tracking surveys, we will recruit LGBT young adults aged 18 to 24
from all campaign cities through social media.
The information collected is necessary to inform FDA's efforts and
measure the effectiveness and public health impact of the campaigns.
Data from the media tracking surveys will be used to estimate awareness
of and exposure to the campaigns among young adults in target markets
where the campaigns are active. Data from the outcome evaluation study
will be used to examine statistical associations between awareness of
and exposure to the campaigns and subsequent changes in specific
outcomes of interest, which will include knowledge, attitudes, beliefs
and intentions related to tobacco use.
FDA's burden estimate is based on prior experience with in-person
studies similar to the Agency's plan presented in this document, as
well as previous
[[Page 37272]]
research using social media advertising to recruit young adult
participants. To reduce overall burden hours, participants who screen
and complete the baseline outcome evaluation questionnaire will be re-
contacted to complete the first follow up campaign evaluation
questionnaire, those who complete the first follow up campaign
evaluation questionnaire will be re-contacted to complete the second
follow up campaign evaluation questionnaire, and so on. Re-contacted
individuals will not need to complete the screener again. We expect a
50 percent response rate for individuals recruited in person and a 30
percent rate for individuals recruited via social media. In each
successive round of data collection, we expect 50 percent of re-
contacted individuals to complete the follow up questionnaire,
therefore, additional screenings will be conducted for each follow up
in order to maintain the target sample size for each follow up
questionnaire.
To obtain the target number of completed questionnaires
(``completes'') for the outcome evaluation study, 18,376 young adults
(11,810 recruited in person and 6,566 recruited via social media) will
participate in a screening process (``screener''). The estimated burden
per screener is 5 minutes (0.083), for a total of 1,525 hours (980
hours for participants recruited in person and 545 hours for persons
recruited via social media). A total of 12,600 LGBT young adults (9,448
of those screened in person and 3,152 of those screened through social
media) will complete questionnaires in 4 rounds of data collection
(baseline and three post-campaign rounds). The estimated burden per
complete is 30 minutes (0.5 hour) for the baseline questionnaire and 40
minutes (0.667 hour) for each follow up complete, for a total of 7,878
hours (5,906 hours for those recruited in person and 1,972 hours for
those recruited via social media).
To obtain the target number of completes for the media tracking
survey, 5,000 young adults will be recruited via social media ads to
complete a screener for all three waves of the media tracking survey.
The estimated burden per screener response is 5 minutes (0.083 hour),
for a total of 414 hours for all waves of media tracking screener. An
estimated 500 LGBT young adults will complete each of the three waves
of the media tracking survey (assuming a 30 percent response rate to
screeners via social media). The estimated burden per completed media
tracking questionnaire is 40 minutes (0.667 hour), for a total of 1,002
hours for the three waves. The total burden for the media tracking
survey (screeners and completes) is 1,416 hours.
The target number of completed campaign questionnaires (screeners
and questionnaires for both the outcome evaluation and media tracking
survey) for all respondents is 37,477. The total estimated burden is
10,819 hours.
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Type of respondent Activity Number of responses per Total annual Average burden per Total hours
respondents respondent responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
General population--Recruited in Screener--Baseline--o 4,724 1 4,724 0.083 (5 min.).............. 392
person (50% response rate). utcome study.
Screener--First 2,362 1 2,362 0.083 (5 min.).............. 196
follow up--outcome
study.
Screener--Second 2,362 1 2,362 0.083 (5 min.).............. 196
follow up--outcome
study.
Screener--Third 2,362 1 2,362 0.083 (5 min.).............. 196
follow up--outcome
study.
LGBT young adults aged 18-24 in Baseline--outcome 2,362 1 2,362 0.5 (30 min.)............... 1181
select media markets--Recruited in evaluation
person. questionnaire.
First follow up young 2,362 1 2,362 0.667 (40 min.)............. 1575
adult outcome
evaluation
questionnaire.
Second follow up 2,362 1 2,362 0.667 (40 min.)............. 1575
young adult outcome
evaluation
questionnaire.
Third follow up young 2,362 1 2,362 0.667 (40 min.)............. 1575
adult outcome
evaluation
questionnaire.
General population--Recruited via Screener--Baseline--o 2,627 1 2,627 0.083 (5 min.).............. 218
social media (30% response rate). utcome study.
Screener--First 1,313 1 1,313 0.083 (5 min.).............. 109
follow up--outcome
study.
Screener--Second 1,313 1 1,313 0.083 (5 min.).............. 109
follow up--outcome
study.
Screener--Third 1,313 1 1,313 0.083 (5 min.).............. 109
follow up--outcome
study.
LGBT young adults aged 18-24 in Baseline--outcome 788 1 788 0.5 (30 min.)............... 394
select media markets--Recruited evaluation
via social media. questionnaire.
First follow up young 788 1 788 0.667 (40 min.)............. 526
adult outcome
evaluation
questionnaire.
[[Page 37273]]
Second follow up 788 1 788 0.667 (40 min.)............. 526
young adult outcome
evaluation
questionnaire.
Third follow up young 788 1 788 0.667 (40 min.)............. 526
adult outcome
evaluation
questionnaire.
LGBT young adults aged 18-24 in the 1st media tracking 1667 1 1667 0.083 (5 min.).............. 138
select media markets--Recruited screener.
via social media.
1st media tracking 500 1 500 0.667 (40 min.)............. 334
questionnaire.
2nd media tracking 1667 1 1667 0.083 (5 min.).............. 138
screener.
2nd media tracking 500 1 500 0.667 (40 min.)............. 334
questionnaire.
3rd media tracking 1667 1 1667 0.083 (5 min.).............. 138
screener.
3rd media tracking 500 1 500 0.667 (40 min.)............. 334
questionnaire.
------------------------------------------------ ---------------
Total.......................... ..................... 37,477 .............. .............. ............................ 10,819
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: June 24, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-16020 Filed 6-29-15; 8:45 am]
BILLING CODE 4164-01-P